Australia markets open in 7 hours 51 minutes

TTOO Jan 2025 1.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.05000.0000 (0.00%)
As of 11:43AM EDT. Market open.
Full screen
Previous close0.0500
Open0.0500
Bid0.0000
Ask0.0000
Strike1.00
Expiry date2025-01-17
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume205
Open interest1.49k
  • GlobeNewswire

    T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

    LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued list

  • GlobeNewswire

    T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,02

  • GlobeNewswire

    T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of